IDF21-0195 Reported pregnancy outcomes with insulin glargine 300 U/mL: a post-marketing survey of pharmacovigilance data

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2022-04, Vol.186, p.109612, Article 109612
Main Authors: Westerbacka, J., Bassole, C., Duverne, M., Doder, Z., Schoepper, H.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 109612
container_title Diabetes research and clinical practice
container_volume 186
creator Westerbacka, J.
Bassole, C.
Duverne, M.
Doder, Z.
Schoepper, H.
description
doi_str_mv 10.1016/j.diabres.2022.109612
format article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1016_j_diabres_2022_109612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822722004247</els_id><sourcerecordid>S0168822722004247</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1492-e7f1653d287b008e335797939c0b835131c3d126bd90118ba5d44f9f7e098d913</originalsourceid><addsrcrecordid>eNqFkNtKAzEQhoMoWKuPIOQFts1hD4k3ItVqoSCIvQ7ZZHabut1dkm21b29qe-_VDMP8Hz8fQveUTCih-XQzsU6XHsKEEcbiTeaUXaARFQVLBGPFJRrFP_G3X6ObEDaEkJyn2Qj9LJ7njCaEygx_QN_5ASzuPdStbs0Bd7vBdFsI-NsNa-zasGtci-tG-9q1gDkheDXdLh-wxn0XhmSr_RcMrq1x2Pk9RECF-7X2W226vatdE6mArR70LbqqdBPg7jzHaDV_-Zy9Jcv318XsaZkYmkqWQFHRPOOWiaIkRADnWSELyaUhpeAZ5dRwS1leWkkoFaXObJpWsiqASGEl5WOUnbjGdyF4qFTvXax5UJSooz61UWd96qhPnfTF3OMpB7Hc3oFXwTiI7a3zYAZlO_cP4RdRl3pO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>IDF21-0195 Reported pregnancy outcomes with insulin glargine 300 U/mL: a post-marketing survey of pharmacovigilance data</title><source>Elsevier</source><creator>Westerbacka, J. ; Bassole, C. ; Duverne, M. ; Doder, Z. ; Schoepper, H.</creator><creatorcontrib>Westerbacka, J. ; Bassole, C. ; Duverne, M. ; Doder, Z. ; Schoepper, H.</creatorcontrib><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2022.109612</identifier><language>eng</language><publisher>Elsevier B.V</publisher><ispartof>Diabetes research and clinical practice, 2022-04, Vol.186, p.109612, Article 109612</ispartof><rights>2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Westerbacka, J.</creatorcontrib><creatorcontrib>Bassole, C.</creatorcontrib><creatorcontrib>Duverne, M.</creatorcontrib><creatorcontrib>Doder, Z.</creatorcontrib><creatorcontrib>Schoepper, H.</creatorcontrib><title>IDF21-0195 Reported pregnancy outcomes with insulin glargine 300 U/mL: a post-marketing survey of pharmacovigilance data</title><title>Diabetes research and clinical practice</title><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkNtKAzEQhoMoWKuPIOQFts1hD4k3ItVqoSCIvQ7ZZHabut1dkm21b29qe-_VDMP8Hz8fQveUTCih-XQzsU6XHsKEEcbiTeaUXaARFQVLBGPFJRrFP_G3X6ObEDaEkJyn2Qj9LJ7njCaEygx_QN_5ASzuPdStbs0Bd7vBdFsI-NsNa-zasGtci-tG-9q1gDkheDXdLh-wxn0XhmSr_RcMrq1x2Pk9RECF-7X2W226vatdE6mArR70LbqqdBPg7jzHaDV_-Zy9Jcv318XsaZkYmkqWQFHRPOOWiaIkRADnWSELyaUhpeAZ5dRwS1leWkkoFaXObJpWsiqASGEl5WOUnbjGdyF4qFTvXax5UJSooz61UWd96qhPnfTF3OMpB7Hc3oFXwTiI7a3zYAZlO_cP4RdRl3pO</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Westerbacka, J.</creator><creator>Bassole, C.</creator><creator>Duverne, M.</creator><creator>Doder, Z.</creator><creator>Schoepper, H.</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202204</creationdate><title>IDF21-0195 Reported pregnancy outcomes with insulin glargine 300 U/mL: a post-marketing survey of pharmacovigilance data</title><author>Westerbacka, J. ; Bassole, C. ; Duverne, M. ; Doder, Z. ; Schoepper, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1492-e7f1653d287b008e335797939c0b835131c3d126bd90118ba5d44f9f7e098d913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Westerbacka, J.</creatorcontrib><creatorcontrib>Bassole, C.</creatorcontrib><creatorcontrib>Duverne, M.</creatorcontrib><creatorcontrib>Doder, Z.</creatorcontrib><creatorcontrib>Schoepper, H.</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Westerbacka, J.</au><au>Bassole, C.</au><au>Duverne, M.</au><au>Doder, Z.</au><au>Schoepper, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IDF21-0195 Reported pregnancy outcomes with insulin glargine 300 U/mL: a post-marketing survey of pharmacovigilance data</atitle><jtitle>Diabetes research and clinical practice</jtitle><date>2022-04</date><risdate>2022</risdate><volume>186</volume><spage>109612</spage><pages>109612-</pages><artnum>109612</artnum><issn>0168-8227</issn><eissn>1872-8227</eissn><pub>Elsevier B.V</pub><doi>10.1016/j.diabres.2022.109612</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0168-8227
ispartof Diabetes research and clinical practice, 2022-04, Vol.186, p.109612, Article 109612
issn 0168-8227
1872-8227
language eng
recordid cdi_crossref_primary_10_1016_j_diabres_2022_109612
source Elsevier
title IDF21-0195 Reported pregnancy outcomes with insulin glargine 300 U/mL: a post-marketing survey of pharmacovigilance data
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T11%3A18%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IDF21-0195%20Reported%20pregnancy%20outcomes%20with%20insulin%20glargine%20300%20U/mL:%20a%20post-marketing%20survey%20of%20pharmacovigilance%20data&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Westerbacka,%20J.&rft.date=2022-04&rft.volume=186&rft.spage=109612&rft.pages=109612-&rft.artnum=109612&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2022.109612&rft_dat=%3Celsevier_cross%3ES0168822722004247%3C/elsevier_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1492-e7f1653d287b008e335797939c0b835131c3d126bd90118ba5d44f9f7e098d913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true